Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association (2003-7) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunologicals section of the Food and Drug Administration Dr. Petrylak was instrumental in the clinical development of docetaxel for prostate cancer, and he chaired one of the trials that supported its approval for prostate cancer by the FDA in 2004. He was also one of the principal investigators on the SPARC trial, an international registration study of satraplatin, an oral chemotherapy agent, for patients who failed on chemotherapeutic regimen for prostate cancer